Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Deregulation of HLA-I in cancer and its central importance for immunotherapy.

Hazini A. et al, (2021), J Immunother Cancer, 9

Polymer stealthing and mucin-1 retargeting for enhanced pharmacokinetics of an oncolytic vaccinia virus.

Hill C. et al, (2021), Mol Ther Oncolytics, 21, 47 - 61

Tackling HLA Deficiencies Head on with Oncolytic Viruses.

Fisher K. et al, (2021), Cancers (Basel), 13

A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR).

O'Cathail SM. et al, (2020), Radiat Oncol, 15

NK Cells Augment Oncolytic Adenovirus Cytotoxicity in Ovarian Cancer.

Leung EYL. et al, (2020), Mol Ther Oncolytics, 16, 289 - 301

External Beam Radiation Therapy and Enadenotucirev: Inhibition of the DDR and Mechanisms of Radiation-Mediated Virus Increase.

Pokrovska TD. et al, (2020), Cancers (Basel), 12

The role of cancer metabolism in defining the success of oncolytic viro-immunotherapy

Dyer A. et al, (2020), Cytokine and Growth Factor Reviews

Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples.

Scott EM. et al, (2019), J Immunother Cancer, 7

Polyvalent Diazonium Polymers Provide Efficient Protection of Oncolytic Adenovirus Enadenotucirev from Neutralizing Antibodies while Maintaining Biological Activity In Vitro and In Vivo.

Francini N. et al, (2019), Bioconjug Chem, 30, 1244 - 1257

A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE).

Machiels J-P. et al, (2019), J Immunother Cancer, 7

An Oncolytic Virus Expressing a T-cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells.

Freedman JD. et al, (2018), Cancer Res, 78, 6852 - 6865

Expression of human CD46 and trans-complementation by murine adenovirus 1 fails to allow productive infection by a group B oncolytic adenovirus in murine cancer cells.

Lei J. et al, (2018), J Immunother Cancer, 6

Optimizing the tolerability of intravenous oncolytic viral immunotherapy administration: A sub-analysis of tolerability and cytokine data from the EVOLVE study of enadenotucirev (EnAd), an oncolytic adenovirus

McElwaine-Johnn H. et al, (2017), Annals of Oncology, 28

Targeting T-cells to human cancer associated fibroblasts using an oncolytic virus expressing a FAP-specific T-cell engager

Champion B. et al, (2017), JOURNAL FOR IMMUNOTHERAPY OF CANCER, 5

Making Oncolytic Virotherapy a Clinical Reality: The European Contribution.

Duffy MR. et al, (2017), Hum Gene Ther, 28, 1033 - 1046

Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection.

Garcia-Carbonero R. et al, (2017), J Immunother Cancer, 5

Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies.

Freedman JD. et al, (2017), EMBO Mol Med, 9, 1067 - 1087

Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes

Marino N. et al, (2017), PLoS ONE, 12

A mechanism of action study of intra-tumoral or intravenous dosing of enadenotucirev, an oncolytic adenovirus in patients with colon, lung, bladder and renal carcinoma undergoing resection of primary tumor

Garcia-Carbonero R. et al, (2016), Annals of Oncology, 27

A phase I/II study of enadenotucirev, a chimeric Ad11/Ad3 oncolytic group B adenovirus, administered intraperitoneally (IP) in platinum-resistant epithelial ovarian cancer: Pharmacokinetic (PK) and tolerability data from phase I

McNeish IA. et al, (2016), JOURNAL OF CLINICAL ONCOLOGY, 34

Load More